

Cancer Research UK Centre for Drug Development: Delivery of High Quality Research Through R&D Partnership



CENTRE FOR DRUG DEVELOPMENT

Sarah Potter, Louisa Essame, Mark Webster-Smith, Claire Goff, Sawretse Leslie, Ye To, Emily Buxton, Karen Dyer, Susan Wan. **Clinical Study Manager Team**, Cancer Research UK Centre for Drug Development (CDD).

Background

Who are the CDD?


The Centre for Drug Development (CDD) goal is to bring much needed new treatments to people with cancer. The CDD sponsors Phase I/II clinical trials of novel agents, providing expertise and facilities to accelerate early phase drug development. This is achieved through close collaboration with the research community, particularly with the clinical and R&D teams from NHS partners across the UK. The importance of a strong working relationship is demonstrated throughout the trial, enabling delivery within budget and timelines.

Who are the Clinical Study Managers?

- Manage early phase oncology trials.
- Lead cross functional study team members across Clinical Operations, Drug safety, Regulatory, Data Management, Project Leaders and Medical Sciences.
- Design, set-up and manage the clinical trial.
- Form collaborative relations with clinical sites, key opinion leaders, and academics.


CDD and R&D Collaboration – How do we collaborate to support opening studies?

The CDD currently has 11 studies in the clinic, collaborating with 20 clinical and R&D teams across the UK.



How do the CDD and R&D collaborate?

HRA- Health Research Authority
NIHR – National Institute for Health Research



CDD & R&D Working Well Together...

- Expedited study opening e.g. LY3143921 study, site specific package sent to The Beatson, Glasgow on 16/02/2017. Trust agreement signed 30/03/2017 with SIV conducted 12/04/2017. Site opened 04/05/2017.
- Earlier R&D input by inviting R&D colleagues to pre study and initiation visits.
- Increased interaction results in familiarity and understanding of how trials are set up and supported at each site which expedites the process for future studies.

Shared Challenges...

- Site resource / time: Phase I/II units and centres participating in multiple studies at one time.
- NIHR metrics: ensuring these are met for additional funding.
- Ensuring logistics and facilities for the trial are in place.
- Continued identification of bottlenecks which delay study open.

Conclusion:

CDD promote early and continued communication to ensure that local capability and capacity are not compromised. It is critical that the CDD and R&D partners work effectively together to deliver the study. Communication with our local R&D colleagues is key to better understand local R&D processes which helps troubleshoot potential issues and also highlight ways in which we can work better together.



For correspondence:
sarah.potter@cancer.org.uk
(MAY 2017)